References

1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.

2. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473-81.

3. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic. Br J Cancer 2009;101:908-15.

4. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fl uorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.

5. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fl uorouracilbased chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-26.

6. Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 2008;38:227-9.

7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. October 2015, Vol. 44 No. 10

8. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fl uorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82.

9. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:1727-33.

10. National Comprehensive Cancer Network. NCCN guidelines for Ovarian Cancer Version 1.2014. Available at: http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Accessed on 15 March 2014.

11. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P; ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii33-40.

12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49.

13. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2011;29:4105-12.

14. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouch O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Defi nitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592-9.

15. Huguet F, Hammel P, Vernerey D, Goldstein D, Van Laethem JL, Glimelius B, et al. Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study. J Clin Oncol 2014;32 (suppl; abstr 4001). Available at: http://meetinglibrary.asco.org/ content/132620-144. Accessed on 15 March 2014.

16. Conroy T, Desseigne F, Ychou M, Bouch O, Guimbaud R, Bcouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med 2011;364:1817-25.

17. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.

18. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouch O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE4/ACCORD 11 randomized trial. J Clin Oncol 2013;31:23-9.

19. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefi t with gemcitabine in fi rst-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.

20. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013;31:1640-8.

21. Cancer Care Ontario. Program in Evidence-based Care (PEBC). Chemotherapy or radiotherapy for resectable pancreatic adenocarcinoma 2-23 Version 2 EBS: June 2013. Available at: https:// www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/gastro-ebs/. Accessed on 15 March 2014.

22. Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K, et al. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol 2014;44:883-8.

23. Pancreatric Section, British Society of Gastroenterology; Pancreatic Society of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; Royal College of Pathologists; Special Interest Group for Gastro-Intestinal Radiology. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005;54;1-16.

24. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Drken B, et al. Best supportive care versus oxaliplatin, folinic acid and 5-fl uorouracil (OFF) plus BSC in patients for second line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676-81.

25. Pelzer U, Kubica K, Stieler J, I Schwaner, G Heil, M Grner, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKOO 003 study. J Clin Oncol 2007;26:4508. Available at: http://meeting.ascopubs.org/cgi/content/short/26/15_ suppl/4508. Accessed on 15 March 2014.

26. Rahma OE, Duffy A, Liewehr, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013;24:1972-1979.